Vaso Corporation Announces Divestiture of Subsidiary
MWN-AI** Summary
Vaso Corporation (OTCQX: VASO), a prominent player in the MedTech industry, announced on November 19, 2025, its decision to divest its subsidiary, VasoHealthcare IT Corp., to Nano-X Imaging Ltd. (Nasdaq: NNOX). This strategic move comes after a thorough review of Vaso's business operations, with the aim to concentrate on core competencies and streamline its portfolio.
VasoHealthcare IT, which operates as a value-added reseller of healthcare IT applications, contributed less than 5% to Vaso’s overall revenue. The terms of the sale entail an overall consideration of up to $800,000, which includes an immediate payment of $200,000 at closing and an earnout of up to $600,000 contingent upon the subsidiary’s post-closing performance. Vaso Corporation intends to utilize the proceeds from this transaction to bolster investments in its remaining business lines and strategic initiatives.
Dr. Jun Ma, Vaso's CEO, expressed optimism regarding the divestiture, stating it represents a positive direction for both shareholders and the VasoHealthcare IT team, as they will join Nanox, a company known for its innovative medical imaging technology. The transaction is expected to close within a few weeks, pending specific conditions.
Vaso Corporation, headquartered in Plainview, New York, operates through three primary segments: VasoHealthcare, VasoTechnology, and VasoMedical, offering a diversified range of products and services in the healthcare sector. The divestiture of VasoHealthcare IT is seen as a significant step in refocusing the company on its key operational strengths.
For more details and investor inquiries, Vaso Corporation can be contacted at its Plainview location or through Jonathan Newton in investor relations.
MWN-AI** Analysis
Vaso Corporation's recent announcement regarding the divestiture of its subsidiary, VasoHealthcare IT Corp., to Nano-X Imaging Ltd. represents a strategic maneuver in the growing MedTech landscape. Valued at up to $800,000, this move highlights Vaso's intent to concentrate on its core competencies and streamline operations.
From an investment perspective, the divestiture is positioned as a positive development for shareholders, as it allows Vaso to reallocate resources towards its more profitable segments—namely VasoTechnology and VasoMedical. The fact that VasoHealthcare IT contributed less than 5% of total revenue implies that the company is focusing on its substantial business areas that constitute the bulk of its profitability.
Investors should view this sale not merely as a financial transaction, but as an opportunity for Vaso to enhance its strategic positioning within the healthcare IT and medical devices sectors. By shedding less profitable segments, Vaso is taking a proactive approach to consolidate its market presence and potentially increase shareholder value.
The $600,000 earnout contingent on post-sale performance could also signal confidence in the future of the VasoHealthcare IT subsidiary as part of a larger entity like Nanox. Successful integration into Nanox’s operations may unlock synergies, enhancing the subsidiary’s growth trajectory, which indirectly bodes well for Vaso's reputation and stock performance.
For prospective investors, monitoring Vaso’s transition post-divestiture will be crucial. Key indicators such as improvements in earnings from core business lines and effective re-investment of the proceeds will be essential in assessing the company’s performance moving forward.
In summary, while the immediate fiscal impact may appear modest, Vaso's strategic divestiture could set the stage for enhanced operational efficiency and growth, making it worth watching for long-term investment potential.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
| Vaso Corporation 137 Commercial Street Plainview, New York 11803 Tel: (516) 997-4600 Fax: (516) 997-2299 |
Investor Contact:
Jonathan Newton
Investor Relations
Phone: 516-997-4600
Email: jnewton@vasocorporation.com
PLAINVIEW, N.Y, Nov. 19, 2025 (GLOBE NEWSWIRE) -- Vaso Corporation (“Vaso”) (OTCQX: VASO), a leading MedTech company with a diversified business portfolio in network and healthcare IT services, professional sales services and proprietary medical products, announced today that it had reached an agreement, subject to certain conditions, with Nano-X Imaging Ltd. (“Nanox”) (Nasdaq: NNOX), an innovative medical imaging technology company, to sell one of its subsidiaries, VasoHealthcare IT Corp. The parties intend to complete the sale within a couple of weeks.
VasoHealthcare IT Corp. (“VasoHealthcare IT”), a healthcare IT application value added reseller, is a division of Vaso’s information technology business segment. “The decision to sell our VasoHealthcare IT subsidiary to Nanox resulted from a strategic review of our lines of business,” Dr. Jun Ma, President and Chief Executive Officer of Vaso, commented on the transaction. “The divestiture of VasoHealthcare IT will allow us to sharpen our focus on our core operations and competencies. We believe the sale of this line of business is a positive development for our shareholders and provides a strong future for the VasoHealthcare IT team as part of Nanox.”
VasoHealthcare IT provides imaging information technology to hospitals and healthcare providers and represented less than 5% of Vaso’s total revenue. The transaction consideration is up to $800,000, with $200,000 payable at closing and up to $600,000 as an earnout based on the post-closing performance of the business. Vaso expects to use the proceeds from the sale to invest in its other business lines and for strategic initiatives.
Advisors
Barley Snyder, LLP acted as legal counsel to Vaso Corporation.
About Vaso
Vaso Corporation (OTCQX: VASO), headquartered in Plainview, New York, is a diversified organization with three core businesses operating as wholly-owned subsidiaries: VasoHealthcare, the professional sales service arm for GEHealthCare's diagnostic imaging and ultrasound products; VasoTechnology, an information technology and managed connectivity leader serving customers in healthcare provision and other sectors; and VasoMedical, the designer and manufacturer of proprietary medical devices including Biox series devices and the developer and operator of the ARCS cloud-based SaaS platform.
For additional information, please visit www.vasocorporation.com or contact us at info@vasocorporation .
Forward Looking Statements. Except for historical information contained in this release, the matters discussed are forward-looking statements that involve risks and uncertainties. When used in this report, words such as “anticipates”, “believes”, “could”, “estimates”, “expects”, “may”, “optimistic”, “plans”, “potential”, “looking forward”, and “intends” and similar expressions, as they relate to the Company or its management, identify forward-looking statements. Such forward-looking statements are based on the beliefs of the Company’s management, as well as assumptions made by and information currently available to the Company’s management. Among the factors that could cause actual results to differ materially are the following: the effect of business and economic conditions, including the possibility of a downturn in the US economy and the continued impact of the COVID-19 pandemic; failure to achieve any portion of the earnout; the effect of the dramatic changes taking place in IT and healthcare; continuation of the GEHC agreement; the impact of competitive technology and products and their pricing; medical insurance reimbursement policies; manufacturing or supplier problems; unforeseen difficulties and delays in product development programs; the actions of regulatory authorities and third-party payers in the United States and overseas; and the risk factors reported from time to time in the Company’s SEC reports. The Company undertakes no obligation to update forward-looking statements as a result of future events or developments.
# # #
FAQ**
How will the divestiture of VasoHealthcare IT Corp. impact Vaso Corp VASO's overall revenue and profitability in the coming quarters?
What strategic initiatives does Vaso Corp VASO plan to pursue with the proceeds from the sale of VasoHealthcare IT Corp. to Nanox?
Can Vaso Corp VASO provide insights into how this sale aligns with its core operations and future growth strategy in MedTech?
What are the anticipated risks associated with the earnout from the sale of VasoHealthcare IT Corp., and how does Vaso Corp VASO plan to mitigate these risks?
**MWN-AI FAQ is based on asking OpenAI questions about Vaso Corp (OTC: VASO).
NASDAQ: VASO
VASO Trading
3.55% G/L:
$0.175 Last:
10,099 Volume:
$0.175 Open:
